Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer

MJ Roobol, R Kranse, CH Bangma, AG van Leenders… - European urology, 2013 - Elsevier
Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …

Prostate cancer mortality in the Finnish randomized screening trial

TP Kilpeläinen, TL Tammela, N Malila… - Journal of the …, 2013 - academic.oup.com
Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019 - Elsevier
Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …

Screening and prostate-cancer mortality in a randomized European study

FH Schröder, J Hugosson, MJ Roobol… - New England journal …, 2009 - Mass Medical Soc
Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …

Prostate-cancer mortality at 11 years of follow-up

FH Schröder, J Hugosson, MJ Roobol… - … England Journal of …, 2012 - Mass Medical Soc
Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit

PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - Elsevier
BACKGROUND: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …

Screening for prostate cancer (PC)—an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC)

FH Schröder - Urologic Oncology: Seminars and Original …, 2008 - Elsevier
Introduction for screening for prostate cancer as a healthcare policy is desirable provided its
effectiveness can be shown in terms of decreasing prostate cancer mortality at an …

Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European Randomised Study …

MJ Roobol, M Kerkhof, FH Schröder, J Cuzick… - European urology, 2009 - Elsevier
BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa)
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

D Ilic, M Djulbegovic, JH Jung, EC Hwang, Q Zhou… - bmj, 2018 - bmj.com
Objective To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to
screen for prostate cancer. Design Systematic review and meta-analysis. Data sources …

[HTML][HTML] Screening for prostate cancer: a review of the ERSPC and PLCO trials

E Eckersberger, J Finkelstein, H Sadri… - Reviews in …, 2009 - ncbi.nlm.nih.gov
The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the
diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the …